EyePoint Pharmaceuticals, Inc. ($EYPT) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.

Recent developments equals happy investors?

A little month ago, its share rose with 35% on the premarket after expanding its exclusive license agreements with Ocumension Therapeutics for the development and commercialization of YUTIQ and DEXYCU in well-known developing Asian markets. Thanks to the expanded agreements, Ocumension Therapeutics made a single $9.5 million payment for the rights to commercialize both products with their own brand names in South Korea and several Asian regions. Earlier this year in January, the companies signed an agreement for the commercialization of DEXYCU. The area contains the post-operative inflammation in Mainland China, Hong Kong, Macau and Taiwan.         

Investors have been more than positive about Eyepoint on social media in recent weeks. If the mood was considered to be a gauge, then all the lights would hit the green. Based on this matter it would give the share a buy status. This could be the result of a recent announcement of the company about the participation at several upcoming Investor Conferences. The frequency of contributions to a share provides an indication of whether the company is currently attracting a lot of interest from investors. Recently there was less discussion than usual about Eyepoint and as a result the attention decreased. This results in a sell status. If these figures are weighed against each other, the final verdict is still a buy status. Also it can be taken in consideration that with the upcoming Investor Conferences more attention is gained.

Do the numbers show the same?

At $0.503 Eyepoint is now –21.41% off the past 50 day moving average (GD50). This leads to the short term assessment, with an advice of selling. However, based on the last 200 days (GD200), the share contains a sell status, taking into account the distance to the GD200 which is -52.99%. In this regard, the share is judged to be a sell for both periods from a technical point of view. The company has a beta value of 1.14 and has seen 971,019 shares been traded in the last trading session.

The performance of Eyepoint within its own sector

Compared to the average annual performance of shares in the healthcare sector, Eyepoint is over 80% lower with a return of -68.01%. The pharmaceutical industry has achieved an average return of 12.73% over the past 12 months. Eyepoint also scores much lower in this respect at 80.74%. This performance of the share over the past year has resulted in a sell rating. Wall Street analysts have a consensus price target for the stock at $2.93, which means that the shares’ value could jump 497.96% from current levels.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.

By Omar